About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 80153 record(s)
Req # A-2024-000261
Adverse Drug Reactions (ADRs). Report numbers: E2B_06680655, E2B_06436087, 1070609.Organization: Health Canada
January 2025
Req # A-2024-000351
Adverse Drug Reaction (ADR). Report number: E2B_06904611.Organization: Health Canada
January 2025
Req # A-2024-000383
Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_07056111. ADRs for Entyvio. Report numbers: E2B_07087551, E2B_07067564, E2B_07058648, 001084675, E2B_07087654, E2B_07094025, E2B_07054910, 001082748, E2B_07064687.Organization: Health Canada
January 2025
Req # A-2024-000385
Adverse Drug Reaction (ADR) for Alunbrig. Report number: E2B_07054884. ADR for Amphetamine aspartate monohydrate/ amphetamine sulfate/ dextroamphetamine saccharate/ dextroamphetamine sulfate. Report number: E2B_07092490. ADRs for Mesalazine.…Organization: Health Canada
January 2025
Req # A-2024-000386
Adverse Drug Reactions (ADRs) for MESALAMINE. Report numbers: E2B_07056269, E2B_07059401, E2B_07057286. ADRs for C1 Esterase Inhibitor (Human). Report numbers: E2B_07094496, E2B_07081568. ADR for GAMMAGARD LIQUID. Report number: 001083422.…Organization: Health Canada
January 2025
Req # A-2024-000402
Adverse Drug Reactions (ADRs) for LEUPROLIDE ACETATE. Report numbers: E2B_05884097, E2B_03885413, E2B_06349809.Organization: Health Canada
January 2025
Req # A-2024-000407
Adverse Drug Reactions (ADRs). Report numbers: E2B_07005511, E2B_07005513, E2B_07009231, E2B_07014005, E2B_07023051, E2B_07028311, E2B_07030292, E2B_07037177, E2B_07052118, E2B_07043792.Organization: Health Canada
January 2025
Req # A-2024-000571
Adverse Drug Reaction (ADR) for Sodium Phenylbutyrat. Report number: E2B_07170828.Organization: Health Canada
January 2025
Req # A-2024-000607
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_07231496, E2B_07231399, E2B_07234714, 001094399, E2B_07193523, E2B_07229838, E2B_07246719, E2B_07231407, 001092342. ADR for Lansoprazole. Report number: E2B_07246226.Organization: Health Canada
January 2025
Req # A-2024-000617
Adverse Drug Reactions (ADRs). Report numbers: E2B_07214947, E2B_07232555, E2B_07229289.Organization: Health Canada
January 2025